Published in J Antimicrob Chemother on February 01, 1987
Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother (1997) 1.20
Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother (1993) 1.07
Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model. Antimicrob Agents Chemother (2003) 0.80
Intraosseous and intravenous administration of antibiotics yields comparable plasma concentrations during experimental septic shock. Acta Anaesthesiol Scand (2015) 0.79
Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis (1974) 5.47
Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 4.89
Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med (1995) 3.45
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis (1999) 3.39
Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother (1972) 3.21
Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis (1992) 3.16
Carbenicillin and hypokalemia. Ann Intern Med (1973) 2.83
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med (1996) 2.75
Centrally mediated decrease in sympathetic tone induced by 2(2,6-dichlorophenylamino)-2 imidazoline (S.T. 155, Catapresan). Eur J Pharmacol (1967) 2.73
Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am J Med Sci (1977) 2.28
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med (1984) 2.17
Evidence for an alpha-sympathomimetic component in the effects of catapresan on vasomotor centres: antagonism by piperoxane. Eur J Pharmacol (1971) 2.15
Pulmonary emphysema: quantitative CT during expiration. Radiology (1996) 2.14
Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother (1986) 2.12
Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis (2001) 2.03
Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis (1978) 1.89
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med (2001) 1.88
Cephradine. Antibacterial activity and clinical effectiveness. Chemotherapy (1973) 1.88
Ca2+ triggers massive exocytosis in Chinese hamster ovary cells. EMBO J (1996) 1.80
Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis (1981) 1.78
Genome screen for asthma and related phenotypes in the French EGEA study. Am J Respir Crit Care Med (2000) 1.75
Comparison of amikacin and gentamicin. Clin Pharmacol Ther (1975) 1.73
Action of -adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneimittelforschung (1973) 1.71
A universal spine tester for in vitro experiments with muscle force simulation. Eur Spine J (1994) 1.65
Antipseudomonal drugs: comparative study of gentamicin, sisomicin and tobramycin in vitro and in human volunteers. Eur J Cancer (1973) 1.64
An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis (1998) 1.63
Antimicrobial activity of the carbenicillin-gentamicin combination against gram-negative bacilli. Am J Med Sci (1970) 1.62
Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis (1982) 1.62
Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother (1979) 1.62
Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis (1992) 1.61
Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis (1986) 1.59
Simultaneous determination of neuromuscular block at the larynx, diaphragm, adductor pollicis, orbicularis oculi and corrugator supercilii muscles. Br J Anaesth (2000) 1.58
Cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155). II. Central sympathetic structures. Eur J Pharmacol (1968) 1.56
[Pharmacologic study of fenfluramine and its optical isomers]. Arch Int Pharmacodyn Ther (1966) 1.55
Evaluation of a new identification system, Crystal Enteric/Non-Fermenter, for gram-negative bacilli. J Clin Microbiol (1995) 1.55
Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest (1972) 1.55
Infections caused by Providence bacilli. Scand J Infect Dis (1974) 1.49
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49
Contig assembly of bacterial artificial chromosome clones through multiplexed fluorescence-labeled fingerprinting. Genomics (1999) 1.48
Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother (1989) 1.48
Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol (1989) 1.48
Antimicrobial activity of tobramycin and gentamicin used in combination with cephalothin and carbenicillin. Am J Med Sci (1973) 1.48
Retroperitoneal lymphangiectasia associated with bilateral renal vein thrombosis. Nephrol Dial Transplant (1997) 1.45
Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin. Antimicrob Agents Chemother (1975) 1.43
Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin. Antimicrob Agents Chemother (1986) 1.43
Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother (1984) 1.41
Bacteriophage types and antibiotic susceptibility of Staphylococcus aureus. Appl Microbiol (1971) 1.40
Clinical significance of Streptococcus milleri. Eur J Clin Microbiol (1985) 1.40
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer (1997) 1.40
Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin Pharmacol Ther (1976) 1.39
A technique for recording sympathetic nerve activity in unanaesthetized dogs. Neuropharmacology (1974) 1.38
Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol (1988) 1.38
Ceftazidime plus teicoplanin versus ceftazidime plus amikacin as empiric therapy for fever in cancer patients with granulocytopenia. Br J Haematol (1990) 1.38
Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. JAMA (1974) 1.38
Health care expenditure in the last months of life. J Health Econ (2000) 1.35
Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections. Rev Infect Dis (1983) 1.33
Translation in vitro of rat brain messenger RNA coding for tubulin and actin. Proc Natl Acad Sci U S A (1975) 1.31
Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis (1988) 1.31
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother (1983) 1.29
In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob Agents Chemother (1992) 1.29
In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam. Antimicrob Agents Chemother (1985) 1.29
Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy. Eur J Cancer Clin Oncol (1984) 1.28
Sedative effects of alpha-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs. Eur J Pharmacol (1971) 1.26
The effects of age, sex, lung size, and hyperinflation on CT lung densitometry. AJR Am J Roentgenol (1996) 1.25
Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol (1975) 1.24
Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother (1987) 1.23
Pneumonia caused by gram-negative bacilli in hospitalized patients presenting malignant disease. Eur J Cancer (1971) 1.22
Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole A/Giudicelli JF, Schmitt H, Boissier JR: Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a new potent beta adrenergic blocking drug. J Pharmacol Exp Ther (1969) 1.22
Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem (1997) 1.21
Effect of mixing on rifampin bactericidal activity against staphylococci. Antimicrob Agents Chemother (1981) 1.21
Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. The EORTC International Antimicrobial Therapy Cooperative Group. N Engl J Med (1987) 1.21
Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis (1992) 1.21
Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer (1973) 1.20
Synergism between amikacin and cefazolin against Klebsiella: in vitro studies and effect on the bactericidal activity of serum. J Infect Dis (1976) 1.20
Ascending myelitis in association with herpes-simplex virus. N Engl J Med (1972) 1.20
Prophylactic antibiotics in oral, pharyngeal and laryngeal surgery for cancer: (a double-blind study). Laryngoscope (1973) 1.19
Antimicrobial effectiveness ofkanamycin, aminosidin, BB-K8, sisomicin, gentamicin and tobramycin combined with carbenicillin or cephalothin against gram-negative rods. J Med Microbiol (1974) 1.19
Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc Natl Acad Sci U S A (1996) 1.19
Lactic acidosis: a metabolic complication of extensive metastatic cancer. Eur J Cancer Clin Oncol (1983) 1.18
Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin. Antimicrob Agents Chemother (1986) 1.17
Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother (1986) 1.17
Central cardiovascular effects of morphinomimetic peptides in dogs. Eur J Pharmacol (1977) 1.16
Factors that influence cancer patients' anxiety following a medical consultation: impact of a communication skills training programme for physicians. Ann Oncol (2006) 1.16